Red Flags Detected
- Insufficient Stockholder Participation To Achieve Quorum (new) — Low shareholder engagement may signal weak retail support or concerns about the proposed dilution.
Theriva Biologics fails to achieve quorum for vote on 16.2M share warrant dilution
Filed April 9, 2026 · Period ending April 9, 2026 · ~1 min read
Key Changes
-
high
Special stockholder meeting on April 9 failed to reach quorum, preventing vote on issuing 16.2 million shares to warrant holders from October 2025 financing deal.
Item 8.01 verify on EDGAR → -
medium
Company contractually obligated to call new stockholder meetings every 60 days until approval obtained or warrants expire, creating ongoing uncertainty.
Item 8.01 verify on EDGAR → -
high
Warrant exercise approval required under October 2025 inducement agreement with institutional investors for up to 16,184,560 common shares.
Item 8.01 verify on EDGAR →
See the full narrative summary and section-by-section diff — create a free account to read more. Takes 30 seconds.
Partner
Trade TOVX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 6:07 PM